ABEONA THERAPEUTICS INC.ABEOEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of novel gene and cell therapies for life-threatening rare genetic diseases. Its pipeline addresses unmet medical needs, serving patient populations across North America and European markets with limited treatment alternatives.
ABEO Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-24.0M
Net Profit
$-5.2M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.10
ABEONA THERAPEUTICS INC. Q3 FY2025 Financial Summary
ABEONA THERAPEUTICS INC. reported revenue of $0 for Q3 FY2025, with a net profit of $-5.2M (up 82.9% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-5.2M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
ABEONA THERAPEUTICS INC. Quarterly Revenue & Net Profit History
ABEONA THERAPEUTICS INC. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-5.2M | N/A |
| Q2 FY2025 | $400.0K | — | $108.8M | 27208.3% |
Income Statement
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Revenue | $400000 | $0 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Assets | $246.2M | $231.1M |
| Liabilities | $82.7M | $59.9M |
| Equity | $163.6M | $171.2M |
Cash Flow
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Operating CF | $-18.8M | $-21.2M |